1. 14‐day reverse hybrid therapy vs 7‐day concomitant therapy in the first‐line treatment of Helicobacter pylori infection. Issue 1 (3rd December 2020) Authors: Chang, Shiuh‐Nan; Shih, Yung‐Hsiung; Lee, Wen‐Ching; Kuo, Ming‐Te; Tsay, Feng‐Woei; Kuo, Li‐Fu; Huang, Wen‐Wei; Shie, Chang‐Bih Journal: Advances in digestive medicine Issue: Volume 9:Issue 1(2022) Page Start: 38 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir. Issue 2 (28th November 2018) Authors: Kuo, Ming‐Te; Hu, Tsung‐Hui; Hung, Chao‐Hung; Wang, Jing‐Houng; Lu, Sheng‐Nan; Tsai, Kai‐Lung; Chen, Chien‐Hung Journal: Alimentary pharmacology & therapeutics Issue: Volume 49:Issue 2(2019) Page Start: 218 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Role of hepatitis B surface antigen in hepatitis B virus relapse after entecavir or tenofovir prophylaxis in patients undergoing cancer chemotherapy. Issue 10 (17th April 2018) Authors: Kuo, Ming‐Te; Tseng, Po‐Lin; Chou, Yeh‐Pin; Chang, Kuo‐Chin; Tsai, Ming‐Chao; Kuo, Yuan‐Hung; Hu, Tsung‐Hui; Hung, Chao‐Hung; Wang, Jing‐Houng; Lu, Sheng‐Nan; Chen, Chien‐Hung Journal: Journal of gastroenterology and hepatology Issue: Volume 33:Issue 10(2018) Page Start: 1766 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗